Last checked at 
OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - For the six months ended June 30, total invoiced sales of LPLDL and SlimBiome as ingredients or final products were GBP1.1 million, up 44% year-on-year.
Looking ahead, company believes it is in a strong position to meet or beat its annual sales forecast.
"We have continued to make progress since the beginning of the current financial year with strong sales growth from a recurring revenue base which is increasing as partners launch new products, extend territories, and build brand presence. This provides a solid base for a sustainable business which will contribute to revenue growth in [second half] and beyond," says Chief Executive Officer Stephen O'Hara.
Current stock price: 49.20 pence, up 5.8%
Year-to-date change: down 15%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
